Compare Consumer Discretionary Select Sector SPDR Fund (XLY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consumer Discretionary Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Consumer Discretionary Select Sector SPDR Fund trades at $114.56, while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XLY | ZTS | |
|---|---|---|
52-Week High | $124.52 | $156.76 |
52-Week Low | $105.64 | $71.91 |
Market Cap | — | $31.95B |
Sector | — | Health |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLY trades at $114.61, down 0.72% on the day, with technical indicators showing a bearish trend as the price approaches key support levels. The ETF faces headwinds from consumer sentiment concerns but maintains 100% analyst buy ratings. Recent news highlights XLY's strong track record in consumer discretionary exposure despite inflationary pressures affecting the sector.
The outlook remains cautiously optimistic with analyst support, though technical weakness and consumer spending risks require monitoring. Investment opportunity lies in potential sector recovery, while risks include persistent inflation and declining consumer confidence affecting discretionary spending patterns.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
